TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01107431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Arabinose and Chromium
Description: Consumed 70 grams of sucrose simultaneously taking a dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose without dietary Supplement
Description: Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
Study: NCT01744600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
Study: NCT04042103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof cream, 1%
Description: Tapinarof cream, 1% applied topically once daily
Study: NCT01750112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrolane VRF20
Description: Injection treatment with Macrolane VRF20
Study: NCT03834415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17038
Description: Oil drops of L. reuteri containing 1x10\>8 CFU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Probiotics
Description: Oil drops mimicking in consistency and flavor to experimental product
Study: NCT04453982

Intervention type: OTHER
Intervention: Human milk donors
Description: Human milk donors for the Rogers Hixon Ontario Human Milk Bank
Study: NCT01250379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard chemotherapy (doublets not allowed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy (doublets not allowed)
Study: NCT00631748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate
Description: At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral Therapy
Description: During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral Therapy
Description: During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
Study: NCT02188875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messages & Fitbit One
Description: The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit One Only
Description: Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
Study: NCT01319409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Double-Bundle ACL Reconstruction
Description: Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Single-Bundle ACL Reconstruction
Description: Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
Study: NCT04418076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A_No feedback
Description: In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B_Automated feedback
Description: For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group C_Automated feedback + Clinician feedback
Description: For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group D_Automated feedback + Social Network feedback
Description: For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
Study: NCT03225053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEP® technique
Description: G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
Study: NCT00644787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 1-day transdermal patch (Titration Phase)
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
Study: NCT04294810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT00644787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 1-day transdermal patch (Double Blind Phase)
Description: Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 3-day transdermal patch (Double Blind Phase)
Description: Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Study: NCT00999531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo, sterile saline
Study: NCT04689529

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative imaging study
Description: MRI, Breast ultrasound sonography, mammography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative imaging study
Description: MRI, Breast ultrasound sonography, mammography
Study: NCT01528514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcuminoids
Description: Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in capsule form, 4 capsules 4 times/day
Study: NCT04901208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine pod
Description: Nicotine pods administered to individuals who use Juul

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pod
Description: Nicotine-free pods administered to individuals who use Juul
Study: NCT03216473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox
Description: Clostridium Botulinum Toxin A 100 U

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Clostridium Botulinum Toxin A 100 U
Study: NCT01984268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Study: NCT02549209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered every 3 weeks for all subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes.
Study: NCT01452152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
Study: NCT04069065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to Once-daily Tacrolimus
Description: * Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml.
Study: NCT03713164

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ellagic Acid
Description: Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
Study: NCT01234272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
Study: NCT02004080

Intervention type: OTHER
Intervention: Intensive Care treatment
Description: intensive care treatment
Study: NCT00716755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone/Olanzapine and PET scans
Description: Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
Study: NCT01380431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Tablets, 40 mg, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: Tablets, 40 mg, single, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: 50% of subjects received the Par formulated product.
Study: NCT03042208

Intervention type: OTHER
Group type: OTHER
Intervention: Self guided handout
Description: Written handout with basic weight management strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: Access to Weight Watchers in-person meetings and online tools
Study: NCT02030743

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visual training
Description: 6 training sessions with computerised visual attention paradigm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual training
Description: 6 training sessions with computerised visual attention paradigm
Study: NCT01332539

Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study

Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study
Study: NCT01295216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile technology to promote lifestyle modification
Description: Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
Study: NCT02613390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI images of the spine taken of anesthetized participant in the operative prone position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Pain and symptom questionnaires completed at baseline and at follow up.
Study: NCT04197115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Complex B
Description: Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
Study: NCT01258907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Repeating intravenous dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin, stable dose
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin, stable dose
Description: Repeating oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: statin, stable dose
Description: Repeating oral dose
Study: NCT01430039

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1

Intervention type: PROCEDURE
Intervention: Blood sample - venous blood 10 ml.
Description: venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
Study: NCT03922698

Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study: NCT01358955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based cognitive intervention
Description: The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
Study: NCT01252225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 % Lidocaine
Description: 600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 % Lidocaine
Description: 100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
Study: NCT03976648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: film-coated tablets of GLPG1690 to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: film-coated tablets of GLPG1690 to be administered orally
Study: NCT03265652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy
Description: Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham therapy
Description: Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
Study: NCT03961438

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
Description: Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
Description: Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
Study: NCT00003496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02042872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.